Nardella, Caterina
 Distribuzione geografica
Continente #
NA - Nord America 1131
EU - Europa 73
AS - Asia 62
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1272
Nazione #
US - Stati Uniti d'America 1129
CN - Cina 42
SE - Svezia 25
TR - Turchia 16
IT - Italia 15
BG - Bulgaria 9
FI - Finlandia 8
BR - Brasile 4
FR - Francia 3
CA - Canada 2
GB - Regno Unito 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BD - Bangladesh 1
BE - Belgio 1
DE - Germania 1
ES - Italia 1
HK - Hong Kong 1
JP - Giappone 1
MY - Malesia 1
NL - Olanda 1
NO - Norvegia 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 1272
Città #
Fairfield 250
Woodbridge 114
Ashburn 113
Wilmington 101
Houston 94
Seattle 93
Cambridge 76
Chandler 70
Princeton 50
San Mateo 43
Ann Arbor 34
Beijing 29
Jacksonville 19
Izmir 16
San Diego 16
Sofia 9
Trento 8
Dearborn 7
Hefei 5
Nanjing 3
Norwalk 3
São Paulo 3
Bratislava 2
Clearwater 2
Phoenix 2
San Francisco 2
Amsterdam 1
Atlanta 1
Baotou 1
Chengdu 1
Como 1
Costa Mesa 1
Helsinki 1
Kemerovo 1
Kuala Lumpur 1
Kunming 1
London 1
Milan 1
Mountain View 1
New York 1
Ottawa 1
Pitesti 1
Raleigh 1
Redmond 1
Saint Paul 1
San Jose 1
San Paolo di Civitate 1
Shenyang 1
Taiyuan 1
Tokyo 1
Toronto 1
Totale 1189
Nome #
Subtle variations in Pten dose determine cancer susceptibility 79
Of model pets and cancer models: an introduction to mouse models of cancer 73
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer 67
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion 67
The APL paradigm and the "co-clinical trial" project 66
Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis 66
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis 61
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition 61
ETS rearrangements and prostate cancer initiation 55
Radiolabeled heparan sulfate immobilized on microplate as substrate for the detection of heparanase activity 54
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events 54
Mechanism of Activation of Human Heparanase Investigated by Protein Engineering 53
Differential requirement of mTOR in postmitotic tissues and tumorigenesis 49
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis 49
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer 48
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence 45
Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein 45
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells 45
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate 44
Editorial: Precision medicine in oncology 44
Faithfull modeling of PTEN loss driven diseases in the mouse 44
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer 43
Pro-senescence therapy for cancer treatment 42
Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence 37
Circulating RNAs in prostate cancer patients 18
Totale 1309
Categoria #
all - tutte 2219
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2219


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20186 0000 00 10 0230
2018/2019110 0000 07 40 0165231
2019/2020483 169918 1645 68100 96405016
2020/2021333 36207935 1347 839 73937
2021/2022235 206018 612 463 18421036
2022/2023119 3865214 00 00 0000
Totale 1309